ReFacto® Antihemophilic Factor (Recombinant) is a purified protein produced by recombinant DNA technology for use in therapy of factor VIII deficiency. ReFacto is a glycoprotein with an approximate molecular mass of 170 kDa consisting of 1438 amino acids. It has an amino acid sequence that is comparable to the 90 + 80 kDa form of factor VIII, and post-translational modifications that are similar to those of the plasma-derived molecule. ReFacto has
functional characteristics comparable to those of endogenous factor VIII.
ReFacto® Antihemophilic Factor (Recombinant) is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
ReFacto is indicated for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.
ReFacto can be of a significant therapeutic value for treatment of hemophilia A in certain patients with inhibitors to factor VIII6. In clinical studies of ReFacto, patients who developed inhibitors on study continued to manifest a clinical response when inhibitor titers were < 10 BU. When an inhibitor is present, the dosage requirement of factor VIII is variable. The dosage can be determined only by a clinical response and by monitoring of circulating factor VIII levels after treatment (see DOSAGE AND ADMINISTRATION).
ReFacto does not contain von Willebrand factor and therefore is not indicated in von Willebrand's disease.
Published Studies Related to Refacto (Antihemophilic Factor)
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. [2000.06]
To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step...
Clinical Trials Related to Refacto (Antihemophilic Factor)
Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting [Active, not recruiting]
Study to evaluate the safety and effectiveness of ReFacto AF for the treatment of severe
hemophilia A in patients who have not yet received treatment for their hemophilia. Study
subjects will be males less than 6 years old who have not taken any clotting factor or other
blood products before the study. The safety and effectiveness of ReFacto AF will be
determined in this study by tests and procedures done at the doctor's office.
Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings [Terminated]
The study will be investigating safety in patients who switch to ReFacto AF from ReFacto and
other Factor VIII products.
Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A [Completed]
The study will consist of two parts: a safety and efficacy period in which all subjects will
participate and a pharmacokinetic analysis period, in which 30 eligible subjects will
participate to compare ReFacto AF and Advate bioequivalency and safety and efficacy of
ReFacto AF in patients with Hemophilia A.
Study Evaluating Refacto For Pharmacovigilance [Completed]
The purpose of this study is to investigate the effectiveness and safety of treatment with
ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk
assessment will be done.
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A [Completed]
Reports of Suspected Refacto (Antihemophilic Factor) Side Effects
Factor Viii Inhibition (25),
Anti Factor Viii Antibody Positive (13),
Post Procedural Haemorrhage (9),
Drug Ineffective (7),
Colitis Ulcerative (3),
Abdominal Pain Upper (3),
Fatigue (3), more >>
Page last updated: 2006-01-31